{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:23:07Z","timestamp":1791469387883,"version":"4.3.4"},"reference-count":281,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003451","name":"University of the Basque Country","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003451","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.drudis.2024.104161","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T03:32:20Z","timestamp":1725679940000},"page":"104161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["P-glycoprotein (P-gp)-driven cancer drug resistance: biological profile, non-coding RNAs, drugs and nanomodulators"],"prefix":"10.1016","volume":"29","author":[{"given":"Yang","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milad","family":"Ashrafizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murtaza M.","family":"Tambuwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gorka","family":"Orive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2024.104161_b0005","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2024.104161_b0010","doi-asserted-by":"crossref","first-page":"587","DOI":"10.7326\/0003-4819-92-5-587","article-title":"Curability of advanced Hodgkin\u2019s disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute","volume":"92","author":"DeVita","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.drudis.2024.104161_b0015","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1056\/NEJM197602192940801","article-title":"Combination chemotherapy as an adjuvant treatment in operable breast cancer","volume":"294","author":"Bonadonna","year":"1976","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2024.104161_b0020","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1200\/JCO.1986.4.10.1493","article-title":"VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors","volume":"4","author":"Bosl","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2024.104161_b0025","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"130","author":"Holohan","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.drudis.2024.104161_b0030","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ijc.28500","article-title":"The network of P-glycoprotein and microRNAs interactions","volume":"135","author":"Lopes-Rodrigues","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.drudis.2024.104161_b0035","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1248\/bpb.b17-00725","article-title":"Advances in studies of P-glycoprotein and its expression regulators","volume":"41","author":"Yano","year":"2018","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.drudis.2024.104161_b0040","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0959-437X(96)80091-8","article-title":"P-glycoprotein and multidrug resistance","volume":"6","author":"Gottesman","year":"1996","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.drudis.2024.104161_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.576559","article-title":"P-glycoprotein: one mechanism, many tasks and the consequences for pharmacotherapy of cancers","volume":"10","author":"Seelig","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2024.104161_b0050","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3390\/molecules23020337","article-title":"Interplay between P-glycoprotein expression and resistance to endoplasmic reticulum stressors","volume":"23","author":"Hano","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2024.104161_b0055","article-title":"Nanotherapeutics approaches to overcome P-glycoprotein-mediated multi-drug resistance in cancer","volume":"40","author":"Halder","year":"2022","journal-title":"Nanomedicine"},{"key":"10.1016\/j.drudis.2024.104161_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108488","article-title":"Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): an updated review","volume":"249","author":"Dong","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.drudis.2024.104161_b0065","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1021\/acs.jmedchem.7b01457","article-title":"Inhibit or evade multidrug resistance P-glycoprotein in cancer treatment","volume":"61","author":"Waghray","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2024.104161_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2014.11.013","article-title":"Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy","volume":"149","author":"Silva","year":"2015","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.drudis.2024.104161_b0075","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.3390\/molecules27072165","article-title":"Natural small molecules in breast cancer treatment: understandings from a therapeutic viewpoint","volume":"27","author":"Islam","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2024.104161_b0080","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1002\/1873-3468.13985","article-title":"Evolutionary history of ATP-binding cassette proteins","volume":"594","author":"Srikant","year":"2020","journal-title":"FEBS Lett"},{"key":"10.1016\/j.drudis.2024.104161_b0085","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s11033-021-06155-w","article-title":"ABC transporter superfamily. An updated overview, relevance in cancer multidrug resistance and perspectives with personalized medicine","volume":"48","author":"Juan-Carlos","year":"2021","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.drudis.2024.104161_b0090","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.pharmthera.2018.06.013","article-title":"Post-translational modifications of transporters","volume":"192","author":"Czuba","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.drudis.2024.104161_b0095","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3390\/life12060897","article-title":"Multidrug resistance of cancer cells and the vital role of P-glycoprotein","volume":"12","author":"Karthika","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.drudis.2024.104161_b0100","doi-asserted-by":"crossref","first-page":"e11171","DOI":"10.1016\/j.heliyon.2022.e11171","article-title":"P-glycoprotein and cancer: what do we currently know?","volume":"8","author":"Heming","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.drudis.2024.104161_b0105","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1126\/science.aar7389","article-title":"Molecular structure of human P-glycoprotein in the ATP-bound, outward-facing conformation","volume":"359","author":"Kim","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.drudis.2024.104161_b0110","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3389\/fonc.2020.00265","article-title":"Perplexing role of P-glycoprotein in tumor microenvironment","volume":"10","author":"Robinson","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2024.104161_b0115","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1590\/S0100-879X1999000800001","article-title":"P-glycoprotein-mediated resistance to chemotherapy in cancer cells: using recombinant cytosolic domains to establish structure-function relationships","volume":"32","author":"Di Pietro","year":"1999","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.drudis.2024.104161_b0120","doi-asserted-by":"crossref","first-page":"13386","DOI":"10.1073\/pnas.1309275110","article-title":"Structures of P-glycoprotein reveal its conformational flexibility and an epitope on the nucleotide-binding domain","volume":"110","author":"Ward","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2024.104161_b0125","doi-asserted-by":"crossref","first-page":"253","DOI":"10.20892\/j.issn.2095-3941.2019.0284","article-title":"ABC transporters and the hallmarks of cancer: roles in cancer aggressiveness beyond multidrug resistance","volume":"17","author":"Muriithi","year":"2020","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.drudis.2024.104161_b0130","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/labinvest.2012.100","article-title":"MDR1-P-glycoprotein behaves as an oncofetal protein that promotes cell survival in gastric cancer cells","volume":"92","author":"Rocco","year":"2012","journal-title":"Lab Invest"},{"key":"10.1016\/j.drudis.2024.104161_b0135","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood.V93.3.1075","article-title":"P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death","volume":"93","author":"Johnstone","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104161_b0140","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1529\/biophysj.105.077743","article-title":"Interaction of transported drugs with the lipid bilayer and P-glycoprotein through a solvation exchange mechanism","volume":"90","author":"Omote","year":"2006","journal-title":"Biophys J"},{"key":"10.1016\/j.drudis.2024.104161_b0145","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1177\/35.12.2890686","article-title":"Immunocytochemical localization of P170 at the plasma membrane of multidrug-resistant human cells","volume":"35","author":"Willingham","year":"1987","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.drudis.2024.104161_b0150","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.biocel.2011.12.009","article-title":"Intracellular trafficking of P-glycoprotein","volume":"44","author":"Fu","year":"2012","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.drudis.2024.104161_b0155","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1021\/cr9000226","article-title":"ABC efflux pump-based resistance to chemotherapy drugs","volume":"109","author":"Eckford","year":"2009","journal-title":"Chem Rev"},{"key":"10.1016\/j.drudis.2024.104161_b0160","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1023\/A:1026732405381","article-title":"Detection of P-glycoprotein in the nuclear envelope of multidrug resistant cells","volume":"32","author":"Calcabrini","year":"2000","journal-title":"Histochem J"},{"key":"10.1016\/j.drudis.2024.104161_b0165","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2174\/1389203023380413","article-title":"Subcellular detection and localization of the drug transporter P-glycoprotein in cultured tumor cells","volume":"3","author":"Molinari","year":"2002","journal-title":"Curr Protein Pept Sci"},{"key":"10.1016\/j.drudis.2024.104161_b0170","first-page":"226","article-title":"Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution","volume":"68","author":"Santi","year":"1995","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.drudis.2024.104161_b0175","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ijc.11659","article-title":"Dynamic and intracellular trafficking of P-glycoprotein-EGFP fusion protein: implications in multidrug resistance in cancer","volume":"109","author":"Fu","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.drudis.2024.104161_b0180","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/(SICI)1097-0215(19980316)75:6<885::AID-IJC11>3.0.CO;2-2","article-title":"Detection of P-glycoprotein in the Golgi apparatus of drug-untreated human melanoma cells","volume":"75","author":"Molinari","year":"1998","journal-title":"Int J Cancer"},{"key":"10.1016\/j.drudis.2024.104161_b0185","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ijc.2910590614","article-title":"P-glycoprotein expression in the Golgi apparatus of multidrug-resistant cells","volume":"59","author":"Molinari","year":"1994","journal-title":"Int J Cancer"},{"key":"10.1016\/j.drudis.2024.104161_b0190","doi-asserted-by":"crossref","first-page":"C1543","DOI":"10.1152\/ajpcell.00068.2006","article-title":"Actin disruption inhibits endosomal traffic of P-glycoprotein-EGFP and resistance to daunorubicin accumulation","volume":"292","author":"Fu","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.drudis.2024.104161_b0195","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1091\/mbc.e02-11-0704","article-title":"Subcellular localization and activity of multidrug resistance proteins","volume":"14","author":"Rajagopal","year":"2003","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.drudis.2024.104161_b0200","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1016\/j.yexcr.2006.09.005","article-title":"P-gp localization in mitochondria and its functional characterization in multiple drug-resistant cell lines","volume":"312","author":"Solazzo","year":"2006","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.drudis.2024.104161_b0205","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.bcp.2006.01.006","article-title":"Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells","volume":"71","author":"Munteanu","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drudis.2024.104161_b0210","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0145-2126(00)00156-9","article-title":"Intracellular P-gp contributes to functional drug efflux and resistance in acute myeloid leukaemia","volume":"25","author":"Ferrao","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.drudis.2024.104161_b0215","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0169-409X(98)00085-4","article-title":"P-glycoprotein, a gatekeeper in the blood-brain barrier","volume":"36","author":"Schinkel","year":"1999","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.drudis.2024.104161_b0220","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1038\/sj.onc.1206948","article-title":"P-glycoprotein: from genomics to mechanism","volume":"22","author":"Ambudkar","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2024.104161_b0225","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1136\/gut.52.12.1788","article-title":"ABC of oral bioavailability: transporters as gatekeepers in the gut","volume":"52","author":"Dietrich","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.drudis.2024.104161_b0230","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.semcancer.2018.09.007","article-title":"Cellular and molecular mechanisms of glioblastoma malignancy: implications in resistance and therapeutic strategies","volume":"58","author":"Bal\u00e7a-Silva","year":"2019","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.drudis.2024.104161_b0235","series-title":"Stress: physiology, biochemistry, and pathology","first-page":"227","article-title":"Multidrug resistance P-glycoprotein (P-gp), glucocorticoids, and the stress response","author":"Bloise","year":"2019"},{"key":"10.1016\/j.drudis.2024.104161_b0240","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood.V83.9.2451.2451","article-title":"P-glycoprotein expression and function in circulating blood cells from normal volunteers","volume":"83","author":"Klimecki","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104161_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e11171","article-title":"P-glycoprotein and cancer: what do we currently know?","volume":"8","author":"Pilotto Heming","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.drudis.2024.104161_b0250","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.wjorl.2018.07.002","article-title":"P-glycoprotein and chronic rhinosinusitis","volume":"4","author":"Miyake","year":"2018","journal-title":"World J Otorhinolaryngol Head Neck Surg"},{"key":"10.1016\/j.drudis.2024.104161_b0255","doi-asserted-by":"crossref","first-page":"19211","DOI":"10.1074\/jbc.M113.450114","article-title":"On the origin of large flexibility of P-glycoprotein in the inward-facing state","volume":"288","author":"Wen","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2024.104161_b0260","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1126\/science.1168750","article-title":"Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding","volume":"323","author":"Aller","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.drudis.2024.104161_b0265","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/bs.acr.2014.10.002","article-title":"Regulation of ABC transporters blood-brain barrier: the good, the bad, and the ugly","volume":"125","author":"Miller","year":"2015","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.drudis.2024.104161_b0270","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1517\/17425255.2013.741589","article-title":"Species differences in drug transporters and implications for translating preclinical findings to humans","volume":"9","author":"Chu","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.drudis.2024.104161_b0275","first-page":"261","article-title":"P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations","volume":"Vol. 201","author":"Cascorbi","year":"2011"},{"key":"10.1016\/j.drudis.2024.104161_b0280","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1152\/physrev.00037.2005","article-title":"Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system","volume":"86","author":"Sarkadi","year":"2006","journal-title":"Physiol Rev"},{"key":"10.1016\/j.drudis.2024.104161_b0285","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/jcp.55.5.332","article-title":"Multidrug resistance related molecules in human and murine lung","volume":"55","author":"Scheffer","year":"2002","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.drudis.2024.104161_b0290","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1124\/jpet.102.042994","article-title":"Constitutive expression of p-glycoprotein in normal lung alveolar epithelium and functionality in primary alveolar epithelial cultures","volume":"304","author":"Campbell","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2024.104161_b0295","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1124\/jpet.107.132225","article-title":"The role of ATP binding cassette transporters in tissue defense and organ regeneration","volume":"328","author":"Huls","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2024.104161_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.101007","article-title":"Effective targeting of breast cancer by the inhibition of P-glycoprotein mediated removal of toxic lipid peroxidation byproducts from drug tolerant persister cells","volume":"71","author":"Szeb\u00e9nyi","year":"2023","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drudis.2024.104161_b0305","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.21873\/anticanres.16900","article-title":"Co-treatment with aripiprazole and vincristine sensitizes P-glycoprotein-overexpressing drug-resistant MCF-7\/ADR breast cancer cells","volume":"44","author":"Shin","year":"2024","journal-title":"Anticancer Res"},{"key":"10.1016\/j.drudis.2024.104161_b0310","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40262-023-01309-4","article-title":"Evaluation of the effect of lorlatinib on CYP2B6, CYP2C9, UGT, and P-glycoprotein substrates in patients with advanced non-small cell lung cancer","volume":"63","author":"Chen","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.drudis.2024.104161_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.176146","article-title":"Novel (-)-arctigenin derivatives inhibit signal transducer and activator of transcription 3 phosphorylation and P-glycoprotein function resensitizing multidrug resistant cancer cells in vitro and in vivo","volume":"960","author":"Yu","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drudis.2024.104161_b0320","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2022.2155814","article-title":"Discovery of benzochromene derivatives first example with dual cytotoxic activity against the resistant cancer cell MCF-7\/ADR and inhibitory effect of the P-glycoprotein expression levels","volume":"38","author":"Al-Harbi","year":"2023","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.drudis.2024.104161_b0325","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.23421","article-title":"Reversal of P-glycoprotein-mediated multidrug resistance by natural N-alkylated indole alkaloid derivatives in KB-ChR-8-5 drug-resistant cancer cells","volume":"37","author":"Bharathiraja","year":"2023","journal-title":"J Biochem Mol Toxicol"},{"key":"10.1016\/j.drudis.2024.104161_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.155210","article-title":"Mosloflavone from Fissistigma petelotii ameliorates oncogenic multidrug resistance by STAT3 signaling modulation and P-glycoprotein blockade","volume":"123","author":"Chien","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.drudis.2024.104161_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216181","article-title":"A multi-functional nano-system combining PI3K-110\u03b1\/\u03b2 inhibitor overcomes P-glycoprotein mediated MDR and improves anti-cancer efficiency","volume":"563","author":"Lin","year":"2023","journal-title":"Cancer Lett"},{"key":"10.1016\/j.drudis.2024.104161_b0340","article-title":"Effective therapy of advanced breast cancer through synergistic anticancer by paclitaxel and P-glycoprotein inhibitor","volume":"26","author":"Zhu","year":"2024","journal-title":"Mater Today Bio"},{"key":"10.1016\/j.drudis.2024.104161_b0345","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202301345","article-title":"Multimodal nanoplatform with ROS amplification to overcome multidrug resistance in prostate cancer via targeting P-glycoprotein and ferroptosis","volume":"13","author":"Guan","year":"2024","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.drudis.2024.104161_b0350","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.3390\/pharmaceutics15122703","article-title":"Enhancing paclitaxel efficacy with piperine-paclitaxel albumin nanoparticles in multidrug-resistant triple-negative breast cancer by inhibiting P-glycoprotein","volume":"15","author":"Xu","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2024.104161_b0355","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ddr.21918","article-title":"Approaches to minimize the effects of P-glycoprotein in drug transport: a review","volume":"83","author":"Husain","year":"2022","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.drudis.2024.104161_b0360","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s11095-007-9347-8","article-title":"Natural and synthetic polymers as inhibitors of drug efflux pumps","volume":"25","author":"Werle","year":"2008","journal-title":"Pharm Res"},{"key":"10.1016\/j.drudis.2024.104161_b0365","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40262-020-00867-1","article-title":"Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: review of clinical drug\u2013drug interaction studies","volume":"59","author":"Elmeliegy","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.drudis.2024.104161_b0370","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrd3028-c1","article-title":"The relevance of assessment of intestinal P-gp inhibition using digoxin as an in vivo probe substrate","volume":"10","author":"Shi","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2024.104161_b0375","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1043-6618(03)00158-0","article-title":"P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement","volume":"48","author":"Varma","year":"2003","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.drudis.2024.104161_b0380","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.xphs.2020.09.017","article-title":"P-glycoprotein substrate assessment in drug discovery: application of modeling to bridge differential protein expression across in vitro tools","volume":"110","author":"Li","year":"2021","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.drudis.2024.104161_b0385","doi-asserted-by":"crossref","first-page":"16856","DOI":"10.1038\/s41598-021-96226-6","article-title":"Structure activity relationships and the binding mode of quinolinone-pyrimidine hybrids as reversal agents of multidrug resistance mediated by P-gp","volume":"11","author":"Laiolo","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2024.104161_b0390","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/2472555220942758","article-title":"P-glycoprotein-mediated efflux using a rapidly maturing Caco2 clone (CLEFF4) in only 5 days without requiring modified growth medium","volume":"26","author":"Crowe","year":"2021","journal-title":"SLAS Discov"},{"key":"10.1016\/j.drudis.2024.104161_b0395","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3390\/pharmaceutics13081261","article-title":"Nanoparticulate drug delivery strategies to address intestinal cytochrome P450 CYP3A4 metabolism towards personalized medicine","volume":"13","author":"Zhang","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2024.104161_b0400","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12876-020-01532-4","article-title":"Overexpression of P-glycoprotein, MRP2, and CYP3A4 impairs intestinal absorption of octreotide in rats with portal hypertension","volume":"21","author":"Sun","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.drudis.2024.104161_b0405","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/01.fpc.0000239974.69464.f2","article-title":"CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure","volume":"17","author":"Sistonen","year":"2007","journal-title":"Pharmacogenet Genom"},{"key":"10.1016\/j.drudis.2024.104161_b0410","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1172\/JCI34007","article-title":"Gut instincts: CYP3A4 and intestinal drug metabolism","volume":"117","author":"Thummel","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2024.104161_b0415","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2174\/1389200219666181003142036","article-title":"Drug\u2013drug interactions of P-gp substrates unrelated to CYP metabolism","volume":"20","author":"Akamine","year":"2019","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.drudis.2024.104161_b0420","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.19102\/icrm.2016.070405","article-title":"Digoxin toxicity caused by an interaction with the novel hepatitis C medication ledipasvir\/sofosbuvir","volume":"7","author":"Valentino","year":"2016","journal-title":"J Innov Card Rhythm Manag"},{"key":"10.1016\/j.drudis.2024.104161_b0425","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1067\/mcp.2003.10","article-title":"Coordinate induction of both cytochrome P4503A and MDR1 by St John\u2019s wort in healthy subjects","volume":"73","author":"Dresser","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.drudis.2024.104161_b0430","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3390\/pharmaceutics3040865","article-title":"Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and beta-lactams","volume":"3","author":"Bolhuis","year":"2011","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2024.104161_b0435","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1172\/JCI6663","article-title":"The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin","volume":"104","author":"Greiner","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2024.104161_b0440","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.critrevonc.2008.02.005","article-title":"Glioblastoma in adults","volume":"67","author":"Brandes","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.drudis.2024.104161_b0445","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11060-011-0749-4","article-title":"Glioblastoma survival in the United States before and during the temozolomide era","volume":"107","author":"Johnson","year":"2012","journal-title":"J Neurooncol"},{"key":"10.1016\/j.drudis.2024.104161_b0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101214","article-title":"TRPC5 mediates TMZ resistance in TMZ-resistant glioblastoma cells via NFATc3-P-gp pathway","volume":"14","author":"Zou","year":"2021","journal-title":"Transl Oncol"},{"key":"10.1016\/j.drudis.2024.104161_b0455","doi-asserted-by":"crossref","first-page":"723","DOI":"10.21873\/anticanres.15530","article-title":"Ko143 reverses MDR in glioblastoma via deactivating P-glycoprotein, sensitizing a resistant phenotype to TMZ treatment","volume":"42","author":"Lustig","year":"2022","journal-title":"Anticancer Res"},{"key":"10.1016\/j.drudis.2024.104161_b0460","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.biopha.2017.03.083","article-title":"\u03b2-Asarone promotes temozolomide\u2019s entry into glioma cells and decreases the expression of P-glycoprotein and MDR1","volume":"90","author":"Wang","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.drudis.2024.104161_b0465","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jconrel.2006.02.014","article-title":"Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition","volume":"112","author":"Lamprecht","year":"2006","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2024.104161_b0470","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","article-title":"Global cancer incidence and mortality rates and trends\u2014an update","volume":"25","author":"Torre","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.drudis.2024.104161_b0475","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10637-019-00781-9","article-title":"Cardamonin, a natural chalcone, reduces 5-fluorouracil resistance of gastric cancer cells through targeting Wnt\/\u03b2-catenin signal pathway","volume":"38","author":"Hou","year":"2020","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.drudis.2024.104161_b0480","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2174\/1566524020666201120113538","article-title":"OSI-027 alleviates oxaliplatin chemoresistance in gastric cancer cells by suppressing P-gp induction","volume":"21","author":"Xu","year":"2021","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.drudis.2024.104161_b0485","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2174\/1871520621666210528144006","article-title":"Celastrol inhibits the proliferation and decreases drug resistance of cisplatin- resistant gastric cancer SGC7901\/DDP cells","volume":"22","author":"Zhan","year":"2022","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.drudis.2024.104161_b0490","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1186\/s12885-021-09020-y","article-title":"Exosomal microRNA-107 reverses chemotherapeutic drug resistance of gastric cancer cells through HMGA2\/mTOR\/P-gp pathway","volume":"21","author":"Jiang","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drudis.2024.104161_b0495","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1080\/01635581.2019.1636102","article-title":"Glucosamine reverses P-glycoprotein-mediated multidrug resistance in the daunorubicin-resistant human gastric cancer cells","volume":"72","author":"Valinezhad Sani","year":"2020","journal-title":"Nutr Cancer"},{"key":"10.1016\/j.drudis.2024.104161_b0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107443","article-title":"PD-1\/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K\/AKT mediated P-gp expression","volume":"94","author":"Wu","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.drudis.2024.104161_b0505","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.drudis.2024.104161_b0510","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1053\/j.gastro.2014.01.013","article-title":"Characteristics of missed or interval colorectal cancer and patient survival: a population-based study","volume":"146","author":"Samadder","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.drudis.2024.104161_b0515","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0140-6736(13)61649-9","article-title":"Colorectal cancer","volume":"383","author":"Brenner","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2024.104161_b0520","article-title":"CAC1 knockdown reverses drug resistance through the downregulation of P-gp and MRP-1 expression in colorectal cancer","volume":"14","author":"Chen","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2024.104161_b0525","doi-asserted-by":"crossref","first-page":"9286","DOI":"10.3390\/ijms22179286","article-title":"S-adenosylmethionine increases the sensitivity of human colorectal cancer cells to 5-fluorouracil by inhibiting P-glycoprotein expression and NF-\u03baB activation","volume":"22","author":"Mosca","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2024.104161_b0530","doi-asserted-by":"crossref","first-page":"7774","DOI":"10.3390\/molecules27227774","article-title":"Dihydrotanshinone I inhibits the proliferation and growth of oxaliplatin-resistant human HCT116 colorectal cancer cells","volume":"27","author":"Wang","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2024.104161_b0535","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/cbf.3604","article-title":"PTPN6 promotes chemosensitivity of colorectal cancer cells via inhibiting the SP1\/MAPK signalling pathway","volume":"39","author":"Fang","year":"2021","journal-title":"Cell Biochem Funct"},{"key":"10.1016\/j.drudis.2024.104161_b0540","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s12072-018-9919-1","article-title":"Goals and targets for personalized therapy for HCC","volume":"13","author":"Couri","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.drudis.2024.104161_b0545","doi-asserted-by":"crossref","first-page":"10209","DOI":"10.3390\/ijms231810209","article-title":"Tumor-promoting actions of HNRNP A1 in HCC are associated with cell cycle, mitochondrial dynamics, and necroptosis","volume":"23","author":"Zhao","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2024.104161_b0550","doi-asserted-by":"crossref","first-page":"6399","DOI":"10.1007\/s11033-023-08492-4","article-title":"Metformin promotes ferroptosis and sensitivity to sorafenib in hepatocellular carcinoma cells via ATF4\/STAT3","volume":"50","author":"Hu","year":"2023","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.drudis.2024.104161_b0555","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12038-020-00065-y","article-title":"Sensitization of hepatocellular carcinoma cells towards doxorubicin and sorafenib is facilitated by glucosedependent alterations in reactive oxygen species, P-glycoprotein and DKK4","volume":"45","author":"Chouhan","year":"2020","journal-title":"J Biosci"},{"key":"10.1016\/j.drudis.2024.104161_b0560","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.3390\/ijms22073315","article-title":"Mitochondrial fuel dependence on glutamine drives chemo-resistance in the cancer stem cells of hepatocellular carcinoma","volume":"22","author":"Lee","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2024.104161_b0565","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s11671-022-03729-w","article-title":"NIR-triggered and ROS-boosted nanoplatform for enhanced chemo\/PDT\/PTT synergistic therapy of sorafenib in hepatocellular carcinoma","volume":"17","author":"Wang","year":"2022","journal-title":"Nanoscale Res Lett"},{"key":"10.1016\/j.drudis.2024.104161_b0570","doi-asserted-by":"crossref","first-page":"35518","DOI":"10.1021\/acsami.1c09610","article-title":"TPGS-galactose-modified polydopamine co-delivery nanoparticles of nitric oxide donor and doxorubicin for targeted chemo-photothermal therapy against drug-resistant hepatocellular carcinoma","volume":"13","author":"Du","year":"2021","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.drudis.2024.104161_b0575","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.drudis.2024.104161_b0580","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/635745","article-title":"Overcoming multidrug resistance in cancer stem cells","volume":"2015","author":"Moitra","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.drudis.2024.104161_b0585","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jbior.2014.05.001","article-title":"Pancreatic cancer stem cells: association with cell surface markers, prognosis, resistance, metastasis and treatment","volume":"56","author":"Fitzgerald","year":"2014","journal-title":"Adv Biol Regul"},{"key":"10.1016\/j.drudis.2024.104161_b0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118518","article-title":"Diltiazem potentiates the cytotoxicity of gemcitabine and 5-fluorouracil in PANC-1 human pancreatic cancer cells through inhibition of P-glycoprotein","volume":"262","author":"El-Mahdy","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.drudis.2024.104161_b0595","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41598-023-27605-4","article-title":"Nanosecond pulsed electric field suppresses growth and reduces multi-drug resistance effect in pancreatic cancer","volume":"13","author":"Szlasa","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2024.104161_b0600","doi-asserted-by":"crossref","first-page":"9839","DOI":"10.2147\/OTT.S253691","article-title":"Emodin reverses gemcitabine resistance of pancreatic cancer cell lines through inhibition of IKK\u03b2\/NF-\u03baB signaling pathway","volume":"13","author":"Tong","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.drudis.2024.104161_b0605","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","article-title":"Ovarian cancer: an integrated review","volume":"35","author":"Stewart","year":"2019","journal-title":"Semin Oncol Nurs"},{"key":"10.1016\/j.drudis.2024.104161_b0610","doi-asserted-by":"crossref","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","article-title":"Epidemiology of ovarian cancer: a review","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.drudis.2024.104161_b0615","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.3390\/ijms23052628","article-title":"The influence of interaction between cadmium with 17\u03b2-estradiol, 2-methoxyestradiol and 16\u03b1-hydroxyestrone on viability and p-glycoprotein in ovarian cancer cell line","volume":"23","author":"Sawicka","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2024.104161_b0620","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3892\/or.2020.7877","article-title":"Osteopontin-c isoform inhibition modulates ovarian cancer cell cisplatin resistance, viability and plasticity","volume":"45","author":"Brum","year":"2021","journal-title":"Oncol Rep"},{"key":"10.1016\/j.drudis.2024.104161_b0625","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3892\/mmr.2021.12135","article-title":"Human epididymis protein 4 promotes P-glycoprotein-mediated chemoresistance in ovarian cancer cells through interactions with Annexin II","volume":"24","author":"Liu","year":"2021","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.drudis.2024.104161_b0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2020.113067","article-title":"Xiaoaiping injection enhances paclitaxel efficacy in ovarian cancer via pregnane X receptor and its downstream molecules","volume":"261","author":"Zhang","year":"2020","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.drudis.2024.104161_b0635","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s12038-019-9851-0","article-title":"LINC00511 knockdown prevents cervical cancer cell proliferation and reduces resistance to paclitaxel","volume":"44","author":"Mao","year":"2019","journal-title":"J Biosci"},{"key":"10.1016\/j.drudis.2024.104161_b0640","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.2147\/DDDT.S252112","article-title":"Leonurine promotes cisplatin sensitivity in human cervical cancer cells through increasing apoptosis and inhibiting drug-resistant proteins","volume":"14","author":"Lin","year":"2020","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.drudis.2024.104161_b0645","first-page":"512","article-title":"PSAT1 upregulation contributes to cell growth and cisplatin resistance in cervical cancer cells via regulating PI3K\/AKT signaling pathway","volume":"50","author":"Duan","year":"2020","journal-title":"Ann Clin Lab Sci"},{"key":"10.1016\/j.drudis.2024.104161_b0650","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3390\/md20100597","article-title":"Cytotoxic N-methylpretrichodermamide B reveals anticancer activity and inhibits P-glycoprotein in drug-resistant prostate cancer cells","volume":"20","author":"Dyshlovoy","year":"2022","journal-title":"Mar Drugs"},{"key":"10.1016\/j.drudis.2024.104161_b0655","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.869461","article-title":"Itraconazole reverts ABCB1-mediated docetaxel resistance in prostate cancer","volume":"13","author":"Lima","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2024.104161_b0660","first-page":"2731","article-title":"Reduced pim-1 expression increases chemotherapeutic drug sensitivity in human androgen-independent prostate cancer cells by inducing apoptosis","volume":"18","author":"Zhang","year":"2019","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.drudis.2024.104161_b0665","doi-asserted-by":"crossref","first-page":"8135","DOI":"10.1021\/acsnano.0c01300","article-title":"Photoactivated H2 nanogenerator for enhanced chemotherapy of bladder cancer","volume":"14","author":"Sun","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.drudis.2024.104161_b0670","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109473","article-title":"Dual delivery nanoscale device for miR-451 and adriamycin co-delivery to combat multidrug resistant in bladder cancer","volume":"122","author":"Wei","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.drudis.2024.104161_b0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2021.153676","article-title":"Long noncoding RNA NORAD acts as a ceRNA mediates gemcitabine resistance in bladder cancer by sponging miR-155-5p to regulate WEE1 expression","volume":"228","author":"Yang","year":"2021","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.drudis.2024.104161_b0680","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3892\/ijo.2023.5567","article-title":"Mechanism of multidrug resistance to chemotherapy mediated by P-glycoprotein (Review)","volume":"63","author":"Tian","year":"2023","journal-title":"Int J Oncol"},{"key":"10.1016\/j.drudis.2024.104161_b0685","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.783317","article-title":"Cajanol sensitizes A2780\/taxol cells to paclitaxel by inhibiting the PI3K\/Akt\/NF-\u03baB signaling pathway","volume":"12","author":"Sui","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2024.104161_b0690","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.molimm.2018.08.010","article-title":"TIPE2 sensitizes osteosarcoma cells to cis-platin by down-regulating MDR1 via the TAK1- NF-\u03baB and - AP-1 pathways","volume":"101","author":"Zhao","year":"2018","journal-title":"Mol Immunol"},{"key":"10.1016\/j.drudis.2024.104161_b0695","first-page":"1030","article-title":"Association between NF-\u03baB expression and drug resistance of liver cancer","volume":"17","author":"Liu","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.drudis.2024.104161_b0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.103051","article-title":"Expression of GnT-III decreases chemoresistance via negatively regulating P-glycoprotein expression: involvement of the TNFR2-NF-\u03baB signaling pathway","volume":"299","author":"Song","year":"2023","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2024.104161_b0705","article-title":"Melatonin increases the chemosensitivity of diffuse large B-cell lymphoma cells to epirubicin by inhibiting P-glycoprotein expression via the NF-\u03baB pathway","volume":"14","author":"Liu","year":"2021","journal-title":"Transl Oncol"},{"key":"10.1016\/j.drudis.2024.104161_b0710","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00280-018-3584-x","article-title":"IL-8 regulates the doxorubicin resistance of colorectal cancer cells via modulation of multidrug resistance 1 (MDR1)","volume":"81","author":"Du","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.drudis.2024.104161_b0715","doi-asserted-by":"crossref","first-page":"6611","DOI":"10.1002\/jcp.27402","article-title":"Chloride channel-3 mediates multidrug resistance of cancer by upregulating P-glycoprotein expression","volume":"234","author":"Chen","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.drudis.2024.104161_b0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153342","article-title":"A multiple-targets alkaloid nuciferine overcomes paclitaxel-induced drug resistance in vitro and in vivo","volume":"79","author":"Liu","year":"2020","journal-title":"Phytomedicine"},{"key":"10.1016\/j.drudis.2024.104161_b0725","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.3892\/or.2016.4730","article-title":"Osthole shows the potential to overcome P-glycoprotein-mediated multidrug resistance in human myelogenous leukemia K562\/ADM cells by inhibiting the PI3K\/Akt signaling pathway","volume":"35","author":"Wang","year":"2016","journal-title":"Oncol Rep"},{"key":"10.1016\/j.drudis.2024.104161_b0730","first-page":"6071","article-title":"(-)-Epigallocatechin-3-gallate down-regulates doxorubicin-induced overexpression of P-glycoprotein through the coordinate inhibition of PI3K\/Akt and MEK\/ERK signaling pathways","volume":"37","author":"Satonaka","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.drudis.2024.104161_b0735","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.2147\/OTT.S186806","article-title":"SMYD2-OE promotes oxaliplatin resistance in colon cancer through MDR1\/P-glycoprotein via MEK\/ERK\/AP1 pathway","volume":"12","author":"Ren","year":"2019","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.drudis.2024.104161_b0740","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.14490","article-title":"TMEM97 knockdown inhibits 5-fluorouracil resistance by regulating epithelial-mesenchymal transition and ABC transporter expression via inactivating the Akt\/mTOR pathway in 5-fluorouracil-resistant colorectal cancer cells","volume":"103","author":"Xu","year":"2024","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.drudis.2024.104161_b0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e27082","article-title":"Jianpi Jiedu decoction reverses 5-fluorouracil resistance in colorectal cancer by suppressing the xCT\/GSH\/GPX4 axis to induce ferroptosis","volume":"10","author":"Ou","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.drudis.2024.104161_b0750","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1007\/s00210-023-02757-2","article-title":"Transglutaminase 3 suppresses proliferation and cisplatin resistance of cervical cancer cells by inactivation of the PI3K\/AKT pathway","volume":"397","author":"Chen","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.drudis.2024.104161_b0755","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s41065-023-00294-9","article-title":"Elevated HMGB1 promotes the malignant progression and contributes to cisplatin resistance of non-small cell lung cancer","volume":"160","author":"Ma","year":"2023","journal-title":"Hereditas"},{"key":"10.1016\/j.drudis.2024.104161_b0760","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3164\/jcbn.22-122","article-title":"Knockdown of LRRK2 inhibits the progression of lung cancer by regulating TLR4\/NF-\u03baB pathways and NLRP3 inflammasome","volume":"73","author":"Wu","year":"2023","journal-title":"J Clin Biochem Nutr"},{"key":"10.1016\/j.drudis.2024.104161_b0765","doi-asserted-by":"crossref","first-page":"e659","DOI":"10.1038\/cddis.2013.193","article-title":"miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer","volume":"4","author":"Karaayvaz","year":"2013","journal-title":"Cell Death Dis"},{"issue":"Suppl. 6","key":"10.1016\/j.drudis.2024.104161_b0770","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1038\/ng1799","article-title":"Strategies to determine the biological function of microRNAs","volume":"38","author":"Kr\u00fctzfeldt","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/j.drudis.2024.104161_b0775","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/ijc.24782","article-title":"Role of microRNA in anticancer drug resistance","volume":"126","author":"Zheng","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.drudis.2024.104161_b0780","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1476-4598-6-60","article-title":"OncomiRs: the discovery and progress of microRNAs in cancers","volume":"6","author":"Cho","year":"2007","journal-title":"Mol Cancer"},{"key":"10.1016\/j.drudis.2024.104161_b0785","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.brainres.2009.06.053","article-title":"MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme","volume":"1286","author":"Li","year":"2009","journal-title":"Brain Res"},{"key":"10.1016\/j.drudis.2024.104161_b0790","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/ijc.23501","article-title":"miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells","volume":"123","author":"Xia","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.drudis.2024.104161_b0795","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.biopha.2016.11.139","article-title":"MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp","volume":"86","author":"Lu","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.drudis.2024.104161_b0800","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2147\/OTT.S286639","article-title":"miR-21 induces chemoresistance in ovarian cancer cells via mediating the expression and interaction of CD44v6 and P-gp","volume":"14","author":"Wang","year":"2021","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.drudis.2024.104161_b0805","doi-asserted-by":"crossref","first-page":"e14016","DOI":"10.1111\/and.14016","article-title":"miR-21 inhibition reverses doxorubicin-resistance and inhibits PC3 human prostate cancer cells proliferation","volume":"53","author":"Zhao","year":"2021","journal-title":"Andrologia"},{"key":"10.1016\/j.drudis.2024.104161_b0810","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.molonc.2013.09.004","article-title":"miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase","volume":"8","author":"Zhou","year":"2014","journal-title":"Mol Oncol"},{"key":"10.1016\/j.drudis.2024.104161_b0815","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bbrc.2014.11.039","article-title":"miR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1","volume":"457","author":"Wan","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2024.104161_b0820","doi-asserted-by":"crossref","first-page":"e12341","DOI":"10.1111\/cpr.12341","article-title":"miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1\/P-gp expression","volume":"50","author":"Zhou","year":"2017","journal-title":"Cell Prolif"},{"key":"10.1016\/j.drudis.2024.104161_b0825","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1016\/j.ajpath.2012.02.024","article-title":"Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298","volume":"180","author":"Bao","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.drudis.2024.104161_b0830","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13046-016-0300-8","article-title":"MiR-302a\/b\/c\/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP\/ERK kinase kinase 1 (MEKK1)","volume":"35","author":"Zhao","year":"2016","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.drudis.2024.104161_b0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2021.110016","article-title":"Hsa-miR-34a-5p reverses multidrug resistance in gastric cancer cells by targeting the 3\u2019-UTR of SIRT1 and inhibiting its expression","volume":"84","author":"Deng","year":"2021","journal-title":"Cell Signal"},{"key":"10.1016\/j.drudis.2024.104161_b0840","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1111\/j.1582-4934.2010.01213.x","article-title":"Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia","volume":"15","author":"Feng","year":"2011","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.drudis.2024.104161_b0845","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1159\/000495552","article-title":"Ginsenoside 20(S)-Rg3 prevents PKM2-targeting miR-324-5p from H19 sponging to antagonize the Warburg effect in ovarian cancer cells","volume":"51","author":"Zheng","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.drudis.2024.104161_b0850","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2147\/OTT.S149908","article-title":"Long noncoding RNA H19 promotes transforming growth factor-\u03b2-induced epithelial-mesenchymal transition by acting as a competing endogenous RNA of miR-370-3p in ovarian cancer cells","volume":"11","author":"Li","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.drudis.2024.104161_b0855","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.7150\/jca.58979","article-title":"LncRNA-H19 regulates chemoresistance to carboplatin in epithelial ovarian cancer through microRNA-29b-3p and STAT3","volume":"12","author":"Tian","year":"2021","journal-title":"J Cancer"},{"key":"10.1016\/j.drudis.2024.104161_b0860","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.21037\/tcr-22-1812","article-title":"Hypoxia upregulates the expression of lncRNA H19 in non-small cell lung cancer cells and induces drug resistance","volume":"11","author":"Li","year":"2022","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.drudis.2024.104161_b0865","doi-asserted-by":"crossref","first-page":"e24460","DOI":"10.1002\/jcla.24460","article-title":"Super enhancer-LncRNA SENCR promoted cisplatin resistance and growth of NSCLC through upregulating FLI1","volume":"36","author":"Shen","year":"2022","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.drudis.2024.104161_b0870","first-page":"995","article-title":"Functional role of circular RNAs in cancer development and progression","volume":"15","author":"Ng","year":"2018","journal-title":"RNA Biol"},{"key":"10.1016\/j.drudis.2024.104161_b0875","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2019.01369","article-title":"Circular RNAs: potential regulators of treatment resistance in human cancers","volume":"10","author":"Jeyaraman","year":"2020","journal-title":"Front Genet"},{"key":"10.1016\/j.drudis.2024.104161_b0880","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10528-021-10080-9","article-title":"Hsa_circ_0006404 and hsa_circ_0000735 regulated ovarian cancer response to docetaxel treatment via regulating p-GP expression","volume":"60","author":"Chen","year":"2022","journal-title":"Biochem Genet"},{"key":"10.1016\/j.drudis.2024.104161_b0885","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1515\/med-2021-0355","article-title":"circ_AKT3 knockdown suppresses cisplatin resistance in gastric cancer","volume":"17","author":"Shi","year":"2022","journal-title":"Open Med"},{"key":"10.1016\/j.drudis.2024.104161_b0890","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s13046-022-02482-3","article-title":"Hsa_circ_0000098 is a novel therapeutic target that promotes hepatocellular carcinoma development and resistance to doxorubicin","volume":"41","author":"Li","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.drudis.2024.104161_b0895","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116984","article-title":"Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p","volume":"239","author":"Dong","year":"2019","journal-title":"Life Sci"},{"key":"10.1016\/j.drudis.2024.104161_b0900","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.molmed.2014.03.002","article-title":"Extracellular vesicles: emerging targets for cancer therapy","volume":"20","author":"Vader","year":"2014","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.drudis.2024.104161_b0905","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1172\/JCI87316","article-title":"Extracellular vesicles: masters of intercellular communication and potential clinical interventions","volume":"126","author":"Pitt","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2024.104161_b0910","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nri855","article-title":"Exosomes: composition, biogenesis and function","volume":"2","author":"Th\u00e9ry","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2024.104161_b0915","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119475","article-title":"Functional extracellular vesicles engineered with lipid-grafted hyaluronic acid effectively reverse cancer drug resistance","volume":"223","author":"Liu","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2024.104161_b0920","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1007\/s10565-023-09812-x","article-title":"Extracellular vesicles derived from paclitaxel-sensitive nasopharyngeal carcinoma cells deliver miR-183-5p and impart paclitaxel sensitivity through a mechanism involving P-gp","volume":"39","author":"Cui","year":"2023","journal-title":"Cell Biol Toxicol"},{"key":"10.1016\/j.drudis.2024.104161_b0925","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13045-024-01535-8","article-title":"Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy","volume":"17","author":"Lu","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.drudis.2024.104161_b0930","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11010-019-03613-9","article-title":"Exosome-mediated transfer of CLIC1 contributes to the vincristine-resistance in gastric cancer","volume":"462","author":"Zhao","year":"2019","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.drudis.2024.104161_b0935","doi-asserted-by":"crossref","first-page":"10773","DOI":"10.1007\/s13277-014-2377-z","article-title":"Exosomes mediate drug resistance transfer in MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein","volume":"35","author":"Lv","year":"2014","journal-title":"Tumour Biol"},{"key":"10.1016\/j.drudis.2024.104161_b0940","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/jso.24614","article-title":"UCH-L1-containing exosomes mediate chemotherapeutic resistance transfer in breast cancer","volume":"115","author":"Ning","year":"2017","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.drudis.2024.104161_b0945","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.11200","article-title":"Cisplatin-resistant HepG2 cell-derived exosomes transfer cisplatin resistance to cisplatin-sensitive cells in HCC","volume":"9","author":"Tang","year":"2021","journal-title":"PeerJ"},{"key":"10.1016\/j.drudis.2024.104161_b0950","doi-asserted-by":"crossref","first-page":"804","DOI":"10.2174\/1389200220666190819151946","article-title":"Cisplatin-resistant MDA-MB-231 cell-derived exosomes increase the resistance of recipient cells in an exosomal miR-423-5p-dependent manner","volume":"20","author":"Wang","year":"2019","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.drudis.2024.104161_b0955","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s10565-021-09675-0","article-title":"microRNA-301b-3p from mesenchymal stem cells-derived extracellular vesicles inhibits TXNIP to promote multidrug resistance of gastric cancer cells","volume":"39","author":"Zhu","year":"2023","journal-title":"Cell Biol Toxicol"},{"key":"10.1016\/j.drudis.2024.104161_b0960","doi-asserted-by":"crossref","first-page":"185","DOI":"10.18632\/oncotarget.27879","article-title":"MicroRNA-214 enriched exosomes from human cerebral endothelial cells (hCEC) sensitize hepatocellular carcinoma to anti-cancer drugs","volume":"12","author":"Semaan","year":"2021","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2024.104161_b0965","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00432-022-04387-2","article-title":"Role of natural P-gp inhibitor in the effective delivery for chemotherapeutic agents","volume":"149","author":"Shah","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.drudis.2024.104161_b0970","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2174\/15680096113139990076","article-title":"P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives","volume":"13","author":"Binkhathlan","year":"2013","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.drudis.2024.104161_b0975","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4137\/DTI.S12519","article-title":"P-glycoprotein inhibition for optimal drug delivery","volume":"7","author":"Amin","year":"2013","journal-title":"Drug Target Insights"},{"key":"10.1016\/j.drudis.2024.104161_b0980","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2174\/1871520615666150113103439","article-title":"Development of fourth generation ABC inhibitors from natural products: a novel approach to overcome cancer multidrug resistance","volume":"15","author":"Karthikeyan","year":"2015","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.drudis.2024.104161_b0985","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114207","article-title":"Design, synthesis, and tumor drug resistance reversal activity of novel hederagenin derivatives modified by nitrogen-containing heterocycles","volume":"232","author":"Huang","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2024.104161_b0990","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8394574","article-title":"Curcumin regulates ERCC1 expression and enhances oxaliplatin sensitivity in resistant colorectal cancer cells through its effects on miR-409-3p","volume":"2020","author":"Han","year":"2020","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.drudis.2024.104161_b0995","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1055\/a-1867-4805","article-title":"Curcumin upregulates miR-148a to increase the chemosensitivity of CD44-positive prostate cancer stem cells to paclitaxel through targeting the MSK1\/IRS1 axis","volume":"72","author":"Vatankhah","year":"2022","journal-title":"Drug Res"},{"key":"10.1016\/j.drudis.2024.104161_b1000","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.bmc.2016.11.023","article-title":"A novel curcumin derivative which inhibits P-glycoprotein, arrests cell cycle and induces apoptosis in multidrug resistance cells","volume":"25","author":"Lopes-Rodrigues","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2024.104161_b1005","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2023.100500","article-title":"Black ginger extract and its active compound, 5,7-dimethoxyflavone, increase intestinal drug absorption via efflux drug transporter inhibitions","volume":"50","author":"Boonnop","year":"2023","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.drudis.2024.104161_b1010","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1080\/00498254.2016.1182233","article-title":"Korean red ginseng extract enhances paclitaxel distribution to mammary tumors and its oral bioavailability by P-glycoprotein inhibition","volume":"47","author":"Bae","year":"2017","journal-title":"Xenobiotica"},{"key":"10.1016\/j.drudis.2024.104161_b1015","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154776","article-title":"Ginsenoside Rb(1) for overcoming cisplatin-insensitivity of A549\/DDP cells in vitro and vivo through the dual-inhibition on two efflux pumps of ABCB1 and PTCH1","volume":"115","author":"Niu","year":"2023","journal-title":"Phytomedicine"},{"key":"10.1016\/j.drudis.2024.104161_b1020","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/med.21739","article-title":"Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp)","volume":"41","author":"Zhang","year":"2021","journal-title":"Med Res Rev"},{"key":"10.1016\/j.drudis.2024.104161_b1025","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.2174\/092986712800167392","article-title":"Three decades of P-gp inhibitors: skimming through several generations and scaffolds","volume":"19","author":"Palmeira","year":"2012","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.drudis.2024.104161_b1030","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100681","article-title":"Medicinal chemistry strategies to discover P-glycoprotein inhibitors: an update","volume":"49","author":"Dong","year":"2020","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drudis.2024.104161_b1035","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.lfs.2018.10.048","article-title":"Structural and functional aspects of P-glycoprotein and its inhibitors","volume":"214","author":"Mollazadeh","year":"2018","journal-title":"Life Sci"},{"key":"10.1016\/j.drudis.2024.104161_b1040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2014.11.002","article-title":"The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade","volume":"18","author":"Kathawala","year":"2015","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drudis.2024.104161_b1045","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.drudis.2024.104161_b1050","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.biopha.2018.02.038","article-title":"Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR","volume":"100","author":"Mohammad","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.drudis.2024.104161_b1055","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1124\/dmd.115.067785","article-title":"Tariquidar is an inhibitor and not a substrate of human and mouse P-glycoprotein","volume":"44","author":"Weidner","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.drudis.2024.104161_b1060","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1126\/science.aav7102","article-title":"Structural insight into substrate and inhibitor discrimination by human P-glycoprotein","volume":"363","author":"Alam","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.drudis.2024.104161_b1065","doi-asserted-by":"crossref","first-page":"5786","DOI":"10.2174\/1381612822666160804093852","article-title":"Kinetic models for measuring P-glycoprotein function at the blood-brain barrier with positron emission tomography","volume":"22","author":"Lubberink","year":"2016","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.drudis.2024.104161_b1070","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s13318-017-0411-4","article-title":"Therapeutic potential and utility of elacridar with respect to P-glycoprotein inhibition: an insight from the published in vitro, preclinical and clinical studies","volume":"42","author":"Dash","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.drudis.2024.104161_b1075","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ejmech.2015.06.049","article-title":"Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives","volume":"101","author":"Li","year":"2015","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2024.104161_b1080","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/cmdc.201402463","article-title":"6,7-Dimethoxy-2-{2-[4-(1H\u20131,2,3-triazol-1-yl)phenyl]ethyl}-1,2,3,4-tetrahydroisoquinolines as superior reversal agents for P-glycoprotein-mediated multidrug resistance","volume":"10","author":"Liu","year":"2015","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drudis.2024.104161_b1085","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1139\/cjpp-2016-0518","article-title":"Reversal of P-glycoprotein-mediated multidrug resistance and pharmacokinetics study in rats by WYX-5","volume":"95","author":"Wang","year":"2017","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.drudis.2024.104161_b1090","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/j.bmc.2016.03.065","article-title":"Design, synthesis and biological evaluation of LBM-A5 derivatives as potent P-glycoprotein-mediated multidrug resistance inhibitors","volume":"24","author":"Wu","year":"2016","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2024.104161_b1095","doi-asserted-by":"crossref","first-page":"25819","DOI":"10.1039\/C6RA02405J","article-title":"Design, synthesis and biological evaluation of novel triazole-core reversal agents against P-glycoprotein-mediated multidrug resistance","volume":"6","author":"Zhang","year":"2016","journal-title":"RSC Adv"},{"key":"10.1016\/j.drudis.2024.104161_b1100","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1016\/j.bmc.2017.06.015","article-title":"Synthesis and biological evaluation of JL-A7 derivatives as potent ABCB1 inhibitors","volume":"25","author":"Pan","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2024.104161_b1105","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1586\/14737140.7.4.447","article-title":"Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor","volume":"7","author":"Fox","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.drudis.2024.104161_b1110","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2174\/1574892815666200717164457","article-title":"Developments in the application of 1, 2, 3-triazoles in cancer treatment","volume":"15","author":"Slavova","year":"2020","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"10.1016\/j.drudis.2024.104161_b1115","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bioorg.2017.01.010","article-title":"Medicinal attributes of 1,2,3-triazoles: current developments","volume":"71","author":"Dheer","year":"2017","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2024.104161_b1120","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2174\/1568026616666160927155515","article-title":"Hybrid compounds as multitarget directed anticancer agents","volume":"17","author":"Kucuksayan","year":"2017","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.drudis.2024.104161_b1125","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ejmech.2017.01.019","article-title":"N-alkanol-N-cyclohexanol amine aryl esters: multidrug resistance (MDR) reversing agents with high potency and efficacy","volume":"127","author":"Teodori","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2024.104161_b1130","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1021\/jacs.6b11188","article-title":"Diverse ortho-C(sp(2))-H functionalization of benzaldehydes using transient directing groups","volume":"139","author":"Liu","year":"2017","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drudis.2024.104161_b1135","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1021\/acs.joc.8b00322","article-title":"Palladium-catalyzed regioselective C-H functionalization of arenes substituted by two N-heterocycles and application in late-stage functionalization","volume":"83","author":"Yin","year":"2018","journal-title":"J Org Chem"},{"key":"10.1016\/j.drudis.2024.104161_b1140","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s00280-004-0905-z","article-title":"A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors","volume":"55","author":"Planting","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.drudis.2024.104161_b1145","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0304-3835(99)00182-2","article-title":"Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter","volume":"146","author":"de Bruin","year":"1999","journal-title":"MXR Cancer Lett"},{"key":"10.1016\/j.drudis.2024.104161_b1150","doi-asserted-by":"crossref","first-page":"6440","DOI":"10.1158\/1078-0432.CCR-07-1335","article-title":"P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan","volume":"13","author":"de Vries","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2024.104161_b1155","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1021\/jm900940f","article-title":"Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood\u2212brain barrier","volume":"52","author":"D\u00f6rner","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2024.104161_b1160","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3389\/fonc.2014.00002","article-title":"Small and innovative molecules as new strategy to revert MDR","volume":"4","author":"Zinzi","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2024.104161_b1165","doi-asserted-by":"crossref","first-page":"8239","DOI":"10.2147\/IJN.S147028","article-title":"Paclitaxel and quercetin nanoparticles co-loaded in microspheres to prolong retention time for pulmonary drug delivery","volume":"12","author":"Liu","year":"2017","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.drudis.2024.104161_b1170","doi-asserted-by":"crossref","first-page":"7654","DOI":"10.1016\/j.biomaterials.2014.05.053","article-title":"Amphiphilic carboxymethyl chitosan-quercetin conjugate with P-gp inhibitory properties for oral delivery of paclitaxel","volume":"35","author":"Wang","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2024.104161_b1175","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2020.117459","article-title":"Chondroitin sulfate-based nanoparticles for enhanced chemo-photodynamic therapy overcoming multidrug resistance and lung metastasis of breast cancer","volume":"254","author":"Shi","year":"2021","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.drudis.2024.104161_b1180","article-title":"Self-assembled nanoparticles of natural bioactive molecules enhance the delivery and efficacy of paclitaxel in glioblastoma","volume":"30","author":"Li","year":"2024","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.drudis.2024.104161_b1185","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.drudis.2024.104161_b1190","doi-asserted-by":"crossref","first-page":"10967","DOI":"10.1021\/acs.chemrev.5b00135","article-title":"Polymeric nanostructures for imaging and therapy","volume":"115","author":"Elsabahy","year":"2015","journal-title":"Chem Rev"},{"key":"10.1016\/j.drudis.2024.104161_b1195","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jconrel.2003.08.005","article-title":"Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles","volume":"93","author":"Vauthier","year":"2003","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2024.104161_b1200","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nmat3776","article-title":"Stimuli-responsive nanocarriers for drug delivery","volume":"12","author":"Mura","year":"2013","journal-title":"Nat Mater"},{"key":"10.1016\/j.drudis.2024.104161_b1205","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12951-019-0540-9","article-title":"pH and redox dual-responsive nanoparticles based on disulfide-containing poly(\u03b2-amino ester) for combining chemotherapy and COX-2 inhibitor to overcome drug resistance in breast cancer","volume":"17","author":"Zhang","year":"2019","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.drudis.2024.104161_b1210","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3892\/ol.2016.5421","article-title":"Solid lipid nanoparticles with TPGS and Brij 78: a co-delivery vehicle of curcumin and piperine for reversing P-glycoprotein-mediated multidrug resistance in vitro","volume":"13","author":"Tang","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.drudis.2024.104161_b1215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.29245\/2578-2967\/2020\/1.1176","article-title":"Aptamer-functionalized hybrid nanoparticles to enhance the delivery of doxorubicin into breast cancer cells by silencing P-glycoprotein","volume":"4","author":"Chandra","year":"2020","journal-title":"J Cancer Treatment Diagn"},{"key":"10.1016\/j.drudis.2024.104161_b1220","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202113671","article-title":"Virus-mimicking cell membrane-coated nanoparticles for cytosolic delivery of mRNA","volume":"61","author":"Park","year":"2022","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.drudis.2024.104161_b1225","article-title":"Cell-membrane-display nanotechnology","volume":"10","author":"Wang","year":"2021","journal-title":"Adv Healthc Mater"},{"key":"10.1016\/j.drudis.2024.104161_b1230","doi-asserted-by":"crossref","first-page":"6527","DOI":"10.1021\/acsnano.2c00893","article-title":"Cell membrane-camouflaged nanocarriers with biomimetic deformability of erythrocytes for ultralong circulation and enhanced cancer therapy","volume":"16","author":"Miao","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.drudis.2024.104161_b1235","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1002\/ctm2.292","article-title":"Membrane engineering of cell membrane biomimetic nanoparticles for nanoscale therapeutics","volume":"11","author":"Zhang","year":"2021","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.drudis.2024.104161_b1240","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202102330","article-title":"Engineered cell membrane-derived nanoparticles in immune modulation","volume":"8","author":"Yang","year":"2021","journal-title":"Adv Sci"},{"key":"10.1016\/j.drudis.2024.104161_b1245","article-title":"Cell\/bacteria-based bioactive materials for cancer immune modulation and precision therapy","volume":"33","author":"Pan","year":"2021","journal-title":"Adv Mater"},{"key":"10.1016\/j.drudis.2024.104161_b1250","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2023.113134","article-title":"Inside-out extracellular vesicles-like biomimetic magnetic nanoparticles for efficient screening P-glycoprotein inhibitors to overcome cancer multidrug resistance","volume":"222","author":"Zhang","year":"2023","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1016\/j.drudis.2024.104161_b1255","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1007\/s11095-016-1998-x","article-title":"Alterations in P-glycoprotein expression and function between macrophage subsets","volume":"33","author":"Cory","year":"2016","journal-title":"Pharm Res"},{"key":"10.1016\/j.drudis.2024.104161_b1260","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.4049\/jimmunol.176.9.5191","article-title":"Dendritic cells require multidrug resistance protein 1 (ABCC1) transporter activity for differentiation","volume":"176","author":"van de Ven","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2024.104161_b1265","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/cei.12067","article-title":"Dendritic cells phenotype fitting under hypoxia or lipopolysaccharide; adenosine 5\u2032-triphosphate-binding cassette transporters far beyond an efflux pump","volume":"172","author":"Lloberas","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.drudis.2024.104161_b1270","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/BF01543107","article-title":"Inhibition of cell-mediated cytolysis and P-glycoprotein function in natural killer cells by verapamil isomers and cyclosporine A analogs","volume":"15","author":"Klimecki","year":"1995","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.drudis.2024.104161_b1275","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0198-8859(98)00112-8","article-title":"Over-expression of multidrug resistance P-glycoprotein inhibits NK granule-mediated lytic ability without affecting the Fas lytic pathway","volume":"60","author":"N\u2019cho","year":"1999","journal-title":"Hum Immunol"},{"key":"10.1016\/j.drudis.2024.104161_b1280","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1529-1049(03)00007-2","article-title":"P-glycoprotein and alloimmune T-cell activation","volume":"4","author":"Pendse","year":"2003","journal-title":"Clin Appl Immunol Rev"},{"key":"10.1016\/j.drudis.2024.104161_b1285","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1158\/0008-5472.CAN-10-0283","article-title":"Selective depletion of CD4+ CD25+ Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2024.104161_b1290","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1084\/jem.20130301","article-title":"Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids","volume":"211","author":"Ramesh","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/j.drudis.2024.104161_b1295","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00401-014-1244-8","article-title":"P-glycoprotein regulates trafficking of CD8+ T cells to the brain parenchyma","volume":"127","author":"Kooij","year":"2014","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.drudis.2024.104161_b1300","doi-asserted-by":"crossref","first-page":"9971","DOI":"10.1073\/pnas.1203543109","article-title":"Regulation of innate CD8+ T-cell activation mediated by cytokines","volume":"109","author":"Freeman","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2024.104161_b1305","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1097\/MIB.0000000000000714","article-title":"Cytokine networks and T-cell subsets in inflammatory bowel diseases","volume":"22","author":"Chen","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.drudis.2024.104161_b1310","first-page":"782","article-title":"Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine","volume":"89","author":"Gerrard","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.drudis.2024.104161_b1315","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/cam4.494","article-title":"P-glycoprotein is expressed and causes resistance to chemotherapy in EBV-positive T-cell lymphoproliferative diseases","volume":"4","author":"Yoshimori","year":"2015","journal-title":"Cancer Med"},{"key":"10.1016\/j.drudis.2024.104161_b1320","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.exphem.2011.01.013","article-title":"Upregulation of mdr1 gene is related to activation of the MAPK\/ERK signal transduction pathway and YB-1 nuclear translocation in B-cell lymphoma","volume":"39","author":"Shen","year":"2011","journal-title":"Exp Hematol"},{"key":"10.1016\/j.drudis.2024.104161_b1325","first-page":"889","article-title":"Generation of multidrug resistant lymphoma cell lines stably expressing P-glycoprotein","volume":"19","author":"Pop","year":"2008","journal-title":"Oncol Rep"},{"key":"10.1016\/j.drudis.2024.104161_b1330","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0928-0987(00)00114-7","article-title":"Multidrug resistance (MDR) in cancer: mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs","volume":"11","author":"Krishna","year":"2000","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.drudis.2024.104161_b1335","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood.V79.2.473.473","article-title":"Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis","volume":"79","author":"Campos","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104161_b1340","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1182\/blood.V81.9.2394.2394","article-title":"Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications","volume":"81","author":"Goasguen","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104161_b1345","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1200\/JCO.1987.5.9.1452","article-title":"P-glycoprotein in human sarcoma: evidence for multidrug resistance","volume":"5","author":"Gerlach","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2024.104161_b1350","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1073\/pnas.84.1.265","article-title":"Expression of a multidrug-resistance gene in human tumors and tissues","volume":"84","author":"Fojo","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2024.104161_b1355","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1200\/JCO.1990.8.4.689","article-title":"Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood","volume":"8","author":"Chan","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2024.104161_b1360","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJM199112053252304","article-title":"P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma","volume":"325","author":"Chan","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2024.104161_b1365","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF00689638","article-title":"P-glycoprotein, multidrug resistance and tumor progression","volume":"13","author":"Bradley","year":"1994","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.drudis.2024.104161_b1370","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2021.100054","article-title":"Exploring new horizons in overcoming P-glycoprotein-mediated multidrug-resistant breast cancer via nanoscale drug delivery platforms","volume":"2","author":"Famta","year":"2021","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"10.1016\/j.drudis.2024.104161_b1375","first-page":"1583","article-title":"Disrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter?","volume":"6","author":"Chung","year":"2016","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.drudis.2024.104161_b1380","first-page":"827","article-title":"RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response","volume":"9","author":"Burger","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2024.104161_b1385","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/jnci\/89.13.917","article-title":"Multidrug resistance in breast cancer: a meta-analysis of MDR1\/gp170 expression and its possible functional significance","volume":"89","author":"Trock","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.drudis.2024.104161_b1390","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/jnci\/89.22.1706","article-title":"P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy","volume":"89","author":"Chan","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.drudis.2024.104161_b1395","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<292::AID-CNCR11>3.0.CO;2-X","article-title":"Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy","volume":"77","author":"Chevillard","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.drudis.2024.104161_b1400","first-page":"1661","article-title":"Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia","volume":"9","author":"Zhou","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2024.104161_b1405","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1182\/blood.V81.2.490.490","article-title":"P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy","volume":"81","author":"Grogan","year":"1993","journal-title":"Blood"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624002861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624002861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T13:14:44Z","timestamp":1731503684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644624002861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":281,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1359644624002861"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2024.104161","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"P-glycoprotein (P-gp)-driven cancer drug resistance: biological profile, non-coding RNAs, drugs and nanomodulators","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2024.104161","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104161"}}